Hi Lopez, you know my views with regards stem cell therapies from my previous postings. In this specific case (Pediatric GVHD), I believe that the data from the trials, the quantitative analysis of of the potency- survival rate relationship (product quality/strength that the company has addressed) and the results of a multitude of studies (in vivo and in vitro) conducted around the world leaves me with little doubt that Remestemcel-L has demonstrated that it is the only ethical and moral treatment available at the moment. When you consider the history and results from Ruxolitinib, Remestemcel-L is a far better alternative with demonstrated superior benefits, specially in those with the most severe cases. Fingers crossed
- Forums
- ASX - By Stock
- FDA ODAC Meeting Material discussion analysis
Hi Lopez, you know my views with regards stem cell therapies...
-
- There are more pages in this discussion • 109 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.13 |
Change
0.000(0.00%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6515 | $1.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 11136 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6515 | 1.180 |
1 | 3801 | 1.175 |
1 | 847 | 1.140 |
5 | 12224 | 1.125 |
10 | 259301 | 1.120 |
Price($) | Vol. | No. |
---|---|---|
1.070 | 11136 | 2 |
1.090 | 10683 | 3 |
1.100 | 30372 | 2 |
1.120 | 422 | 1 |
1.125 | 38012 | 4 |
Last trade - 10.01am 18/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
Day chart unavailable